アブストラクト
| Title | 進行肝癌に対する分子標的治療薬 |
|---|---|
| Subtitle | 特集 肝癌の新たな流れと治療の進歩 |
| Authors | 葛谷貞二*, 川部直人*, 廣岡芳樹* |
| Authors (kana) | |
| Organization | *藤田医科大学消化器内科 |
| Journal | 医学と薬学 |
| Volume | 78 |
| Number | 4 |
| Page | 371-376 |
| Year/Month | 2021 / 4 |
| Article | 報告 |
| Publisher | 自然科学社 |
| Abstract | 「はじめに」 ここ数年, 肝細胞癌(HCC)に対する薬物療法の進歩が著しい. 2009年以降, 長らくSorafenib単独の期間が続いたが, 2017年にRegorafenib, 2018年にLenvatinib, 2019年にRamucirumab, 2020年にCabozantinibが加わり, 現在, 実臨床で使用可能な分子標的治療薬は5剤となった. 第III相臨床試験(IMbrave150試験)にて, がん免疫療法であるAtezolizumab(抗PD-L1抗体)とBevacizumab(抗VEGF-A抗体)の併用療法が, 標準一次治療薬Sorafenibに対する全生存期間(OS)において優越性を示した. この結果に基づき, 薬物療法における一次治療の第一選択は, それまでのSorafenibもしくはLenvatinibに替わって, Atezolizumab+Bevacizumabとなった(2020年9月). |
| Practice | 医学総合 |
| Keywords | 肝細胞癌, 分子標的治療薬, シークエンシャル治療, Cabozantinib |
- 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
参考文献
- 1) Finn RS, Qin S, Ikeda M, et al:Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Car-cinoma. N Engl J Med 382:1894-1905,2020.
- 2) Llovet JM, Villanueva A, Marrero JA, et al:Trial Design and Endpoints in Hepatocellular Carci-noma:AASLD Consensus Conference. Hepatology, 2020.
- 3) Marrero JA, Kulik LM, Sirlin CB, et al:Diagnosis, Staging, and Management of Hepatocellular Car-cinoma:2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepa-tology 68:723-750,2018.
- 4) Llovet JM, Ricci S, Mazzaferro V et al:Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 24:378-390,2008.
- 5) Kudo M, Finn RS, Qin S, et al:Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a ran-domised phase 3 non-inferiority trial. Lancet 391:1163-1173,2018.
残りの17件を表示する
- 6) Raoul JL, Kudo M, Finn RS, et al:Systemic ther-apy for intermediate and advanced hepatocellular carcinoma:Sorafenib and beyond. Cancer Treat Rev 68:16-24,2018.
- 7) Kuzuya T, Asahina Y, Tsuchiya K, et al:Early decrease in α-fetoprotein, but not des-γ-car-boxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 81:251-258,2011.
- 8) Kuzuya T, Ishigami M, Ishizu Y, et al:Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellu-lar Carcinoma. PLoS One 10:e0138776,2015.
- 9) Otsuka T, Eguchi Y, Kawazoe S, et al:Skin tox-icities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res 42:879-886,2012.
- 10) Kuzuya T, Ishigami M, Ishizu Y, et al:Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma. Oncology 91:261-266,2016.
- 11) Kuzuya T, Ishigami M, Ito T, et al:Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. Hepatol Res 50:374-381,2020.
- 12) Takahashi A, Moriguchi M, Seko Y, et al:Impact of Relative Dose Intensity of Early-phase Len-vatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. Anticancer Res 39:5149-5156,2019.
- 13) Maruta S, Ogasawara S, Ooka Y, et al:Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepa-tocellular Carcinoma. Liver Cancer 9:382-396,2020.
- 14) Kuzuya T, Ishigami M, Ito T, et al:Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Anticancer Res 40:2283-2290,2020.
- 15) Tanaka T, Kuzuya T, Ishigami M, et al:Efficacy and Safety of Sorafenib in Unresectable Hepa-tocellular Carcinoma with Bile Duct Invasion. Oncology 98:621-629,2020.
- 16) Bruix J, Qin S, Merle P, et al:RESORCE Investigators:Regorafenib for patients with hepa-tocellular carcinoma who progressed on sorafenib treatment(RESORCE): a randomised, dou-ble-blind, placebo-controlled, phase 3 trial. Lancet 389:56-66,2017.
- 17) Zhu AX, Kang YK, Yen CJ, et al:Ramucirumab after sorafenib in patients with advanced hepa-tocellular carcinoma and increased α-fetoprotein concentrations(REACH-2): a randomised, dou-ble-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:282-296,2019.
- 18) Finn RS, Merle P, Granito A, et al:Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC:Additional analyses from the phase III RESORCE trial. J Hepatol 69:353-358,2018.
- 19) Kuzuya T, Ishigami M, Ito T, et al:Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carci-noma after sorafenib treatment. Hepatol Res 49:1054-1065,2019.
- 20) Kuzuya T, Ishigami M, Ishizu Y, et al:Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Sec-ond-Line Regorafenib Treatment. Oncology 95:91-99,2018.
- 21) Kuzuya T, Ishigami M, Ito T, et al:Initial expe-rience of ramucirumab treatment after lenvatinib failure for patients with advanced hepatocellular carcinoma. Anticancer Res 40:2089-2093,2020.
- 22) Abou-Alfa GK, Meyer T, Cheng AL, et al:Cabozantinib in Patients with Advanced and Pro-gressing Hepatocellular Carcinoma. N Engl J Med 379:54-63,2018.
